Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...

Please provide your email address to receive an email when new articles are posted on . Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s ...

man-injection-0316 The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass. Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 ...